Patents by Inventor Jeffrey L. Browning

Jeffrey L. Browning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20130259861
    Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 20, 2012
    Publication date: October 3, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Evan BECKMAN, Graham K. FARRINGTON, Werner MEIER, Jeffrey L. BROWNING
  • LTBR BLOCKADE: METHODS FOR OPTIMIZING THERAPEUTIC RESPONSIVENESS OF PATIENTS
    Publication number: 20130216557
    Abstract: The invention provides compositions and methods for predicting therapeutic responsiveness of a subject having an autoimmune disorder to an agent that inhibits signaling via LT?R based on the level of expression of IFN or a marker thereof in the subject. The invention also provides methods of treating selected subjects with agents that inhibit or reduce signaling vial LT?R.
    Type: Application
    Filed: August 15, 2011
    Publication date: August 22, 2013
    Applicant: Biogen Idec MA Inc.
    Inventors: Jadwiga Bienkowska, Jeffrey L. Browning
  • Method for the High Level Expression of Active Lymphotoxin-Beta Receptor Immunoglobulin Chimeric Proteins and Their Purification
    Publication number: 20130196376
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Application
    Filed: July 19, 2012
    Publication date: August 1, 2013
    Applicant: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Konard Miatkowski, Werner Meier
  • Methods for inhibiting lymphotoxin-? receptor signaling in TH1 cell-associated disorders
    Patent number: 8455445
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: June 4, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Compositions comprising variant LT-B-R-IG fusion proteins
    Patent number: 8338376
    Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: December 25, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Evan Beckman, Graham K. Farrington, Werner Meier, Jeffrey L. Browning
  • Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
    Patent number: 8287874
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: October 16, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
  • Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins
    Patent number: 8283138
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: October 9, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Konrad Miatkowski, Werner Meier
  • TREATMENT OF DEMYELINATING DISORDERS WITH SOLUBLE LYMPHOTOXIN-BETA-RECEPTOR
    Publication number: 20120244153
    Abstract: The invention relates to the treatment of demyelinating disorders, e.g. multiple sclerosis, using a soluble lymphotoxin beta receptor (LT?R) as an inhibitor of the lymphotoxin pathway.
    Type: Application
    Filed: October 18, 2011
    Publication date: September 27, 2012
    Applicants: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, BIOGEN IDEC MA INC.
    Inventors: Jeffrey L. BROWNING, Jenny P-Y TING
  • SOLUBLE LYMPHOTOXIN-BETA RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES
    Publication number: 20120156214
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Application
    Filed: June 10, 2010
    Publication date: June 21, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey L. BROWNING, Paula S. HOCHMAN, Paul D. RENNERT, Fabienne MACKAY
  • Treatment of demyelinating disorders with soluble lymphotoxin-?-receptor
    Patent number: 8067375
    Abstract: Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: November 29, 2011
    Assignees: Biogen Idec MA Inc., University of North Carolina at Chapel Hill
    Inventors: Jeffrey L. Browning, Jenny P-Y Ting
  • SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING
    Publication number: 20110250200
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Application
    Filed: February 28, 2011
    Publication date: October 13, 2011
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey L. BROWNING, Christopher D. BENJAMIN, Paula S. HOCHMAN
  • Soluble lymphotoxin-? receptor fusion protein and methods for inhibiting lymphotoxin ?-receptor signaling
    Patent number: 7951371
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-?.receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-?. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 31, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents
    Patent number: 7947271
    Abstract: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: May 24, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Veronique Bailly, Ellen Garber
  • TAJ in Neuronal Function
    Publication number: 20110052500
    Abstract: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
    Type: Application
    Filed: August 17, 2010
    Publication date: March 3, 2011
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha Mi, Jeffrey L. Browning
  • SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING
    Publication number: 20110046073
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-?-receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-?.receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-?.receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 24, 2011
    Applicant: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Methods of promoting neurite outgrowth with soluble TAJ polypeptides
    Patent number: 7846438
    Abstract: The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: December 7, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, Jeffrey L. Browning
  • RECEPTOR COUPLING AGENTS AND THERAPEUTIC USES THEREOF
    Publication number: 20100266542
    Abstract: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
    Type: Application
    Filed: January 26, 2010
    Publication date: October 21, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey L. BROWNING, Veronique BAILLY, Ellen GARBER
  • Receptor coupling agents and compositions thereof
    Patent number: 7799902
    Abstract: Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: September 21, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Veronique Bailly, Ellen Garber
  • Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
    Patent number: 7744891
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: June 29, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
  • TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20100111952
    Abstract: Methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. Improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof, are also described.
    Type: Application
    Filed: September 15, 2009
    Publication date: May 6, 2010
    Inventors: Evan Beckman, Graham K. Farrington, Werner Meier, Jeffrey L. Browning